Logo

American Heart Association

  2
  0


Final ID: Mo3069

Predictive Potential of 12-Lead Electrocardiography for Left Ventricular Ejection Fraction: A Comparison between Regression Analysis and Classification.

Abstract Body (Do not enter title and authors here): Introduction: Recent research has demonstrated the ability of artificial intelligence (AI) to categorize patients with reduced left ventricular ejection fraction (LVEF) using 12-lead electrocardiograms (ECGs). However, there remains a gap in research concerning the continuous prediction of LVEF values, despite its potential clinical significance.
Hypothesis: We hypothesized that continuous prediction of LVEF values is achievable using 12-lead electrocardiograms.
Aims: Our aim was to develop predictive models for LVEF, both as a continuous outcome and as a binary outcome using a defined cutoff value of 40%.
Methods: This retrospective, cross-sectional, two-center study comprised 21,471 patients who underwent echocardiography and ECG within a 2-week period. One center contributed data for model derivation (14,203 patients), while the other served for external validation (7,268 patients). We employed four distinct machine learning methodologies encompassing regression and classification tasks, each with unique conceptual frameworks. Predictive variables included age, gender, and 10 parameters from ECGs, commonly measurable automatically with standard 12-lead ECGs. Additionally, conditional branching was performed based on the presence of atrial fibrillation (AF) during ECG recording due to the absence of P-axis and P-R interval in AF patients.
Results: In regression analyses, the R-squared values for all four machine learning methodologies were less than 0.75 for both non-AF and AF patients in internal testing, and even lower in external validation (each R-squared < 0.25). Conversely, for LVEF classification in internal validation, area under curves (AUCs) for detecting LVEF<40% ranged from 0.93 to 1.0 in non-AF patients and 0.88 to 1.0 in AF patients. In external validation, these AUCs ranged from 0.78 to 0.90 in non-AF patients and 0.72 to 0.81 in AF patients.
Conclusions: Consistent with prior studies, the classification of reduced LVEF using electrocardiograms demonstrates high predictive value, especially in the absence of AF. However, continuous value estimation through regression proves challenging, revealing inherent limitations in LVEF prediction solely from electrocardiographic data.
  • Kawakami, Hiroshi  ( Ehime University Graduate School of Medicine , Toon , Japan )
  • Doi, Yohei  ( Ehime University Graduate School of Medicine , Toon , Japan )
  • Luo, Yan  ( Kyoto University Graduate School of Medicine , Kyoto , Japan )
  • Yamamoto, Kazumichi  ( Kyoto University Graduate School of Medicine , Kyoto , Japan )
  • Saito, Makoto  ( Kitaishikai Hospital , Ozu , Japan )
  • Nishimura, Kazuhisa  ( Ehime University Graduate School of Medicine , Toon , Japan )
  • Inoue, Katsuji  ( Ehime University Graduate School of Medicine , Toon , Japan )
  • Ikeda, Shuntaro  ( Ehime University Graduate School of Medicine , Toon , Japan )
  • Yamaguchi, Osamu  ( Ehime University Graduate School of Medicine , Toon , Japan )
  • Author Disclosures:
    Hiroshi Kawakami: DO NOT have relevant financial relationships | Yohei Doi: No Answer | Yan Luo: DO NOT have relevant financial relationships | Kazumichi Yamamoto: DO NOT have relevant financial relationships | Makoto Saito: DO NOT have relevant financial relationships | Kazuhisa Nishimura: No Answer | Katsuji Inoue: DO NOT have relevant financial relationships | Shuntaro Ikeda: No Answer | Osamu Yamaguchi: DO have relevant financial relationships ; Speaker:AstraZeneca K.K.:Active (exists now) ; Speaker:Viatris:Active (exists now) ; Speaker:Eli Lilly Japan K.K.:Active (exists now) ; Speaker:Alnylam Japan:Active (exists now) ; Speaker:Amgen Astellas BioPharma:Active (exists now) ; Speaker:Astellas Pharma Inc.:Active (exists now) ; Speaker:MSD:Active (exists now) ; Speaker:Sumitomo Dainippon Pharma Co., Ltd.:Active (exists now) ; Speaker:Medtronic Japan:Active (exists now) ; Speaker:ONO PHARMACEUTICAL CO., LTD.:Active (exists now) ; Speaker:Nippon Boehringer Ingelheim Co., Ltd.:Active (exists now) ; Speaker:Bayer Yakuhin, Ltd. :Active (exists now) ; Speaker:Novartis Japan:Active (exists now) ; Speaker:DAIICHI SANKYO COMPANY, LIMITED:Active (exists now) ; Speaker:Otsuka Pharmaceutical.:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Echoes and ECGs: How AI Is Revolutionizing Pillars of Cardiovascular Diagnostics

Monday, 11/18/2024 , 10:30AM - 11:30AM

Abstract Poster Session

More abstracts on this topic:
A Deep Learning Topic Analysis Approach for Enhancing Risk Assessment in Heart Failure Using Unstructured Clinical Notes

Adejumo Philip, Pedroso Aline, Khera Rohan

An ECG-based Heart Failure Screening Tool for People with Sickle Cell Disease

Karabayir Ibrahim, Davis Robert, Chinthala Lokesh, Rai Parul, Mcguir Dan, Hankins Jane Silva, Akbilgic Oguz

More abstracts from these authors:
Osteochondrogenic transdifferentiation of vascular smooth muscle cells and microenvironmental dynamics in medial arterial calcification at single-cell resolution

Nakao Yasuhisa, Sakaue Tomohisa, Shirai Manabu, Inoue Katsuji, Ikeda Shuntaro, Yamaguchi Osamu

Remote Dielectric Sensing Predicts Elevated Left Atrial Pressure in Patients With Atrial Fibrillation

Tamaki Shunsuke, Higaki Akinori, Seike Fumiyasu, Higashi Haruhiko, Nishimura Kazuhisa, Ikeda Shuntaro, Yamaguchi Osamu, Inoue Katsuji, Kawakami Hiroshi, Fujisawa Tomoki, Miyabe Ryo, Nakao Yasuhisa, Miyazaki Shigehiro, Akazawa Yusuke, Miyoshi Toru

You have to be authorized to contact abstract author. Please, Login
Not Available